Effects of genetic polymorphisms of ERCC1, XRCC1, GSTP1, ABCB1, and CYP on prognosis of patients with non-small cell lung cancer receiving platinum-based chemotherapy

Aim: Lung cancer has the greatest mortality rates among both men and women and is the primary cause of cancer-related fatalities globally. The effectiveness of chemotherapy as a treatment for lung cancer varies greatly from patient to patient. Genetic factors affect the effectiveness of chemotherapy. Material and Methods: Age of patients, types of lung cancer, smoking status, genetic profiles (ERCC-C8062A, ERCC-G28152A, GSTP1-A313G, ABCB1-C1236T, ABCB1-C3435T, CYP3A52B, CYP3A41B), clinical stages of cancer, and treatment were evaluated by Kaplan-Meier estimates, and a Cox regression model was conducted to assess survival probability and hazard of death of different groups. Results: Cox regression analysis revealed that ABCB1-C1236T and ABCB1-C3435T wild and heterozygous alleles, smoking, adenocarcinoma, and other types of cancer were used for predicting progression time in advanced-stage lung cancer patients. However, no variables were found to be significant predictors of progression time in early-stage lung cancer patients. Conclusions: Overall, our results imply that genetic variables may play a substantial influence in the rate of lung cancer progression and emphasize the need for tailored medication in the treatment of this disease. Discovering genetic markers that can predict the advancement time of lung cancer could assist clinicians in customizing treatment approaches for individual patients and improving the prognosis for people afflicted with this dreadful disease.